Relmada Therapeutics (RLMD) Expected to Announce Quarterly Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) is expected to issue its Q4 2025 results after the market closes on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:30 PM ET.

Relmada Therapeutics Stock Performance

NASDAQ:RLMD opened at $6.18 on Tuesday. The company has a market capitalization of $453.18 million, a price-to-earnings ratio of -3.43 and a beta of 0.72. The stock has a 50-day simple moving average of $4.35 and a 200 day simple moving average of $3.45. Relmada Therapeutics has a one year low of $0.24 and a one year high of $7.51.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Lucid Cap Mkts raised shares of Relmada Therapeutics to a “strong-buy” rating in a report on Monday, March 2nd. Jefferies Financial Group started coverage on Relmada Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $9.00 price objective for the company. Zacks Research upgraded shares of Relmada Therapeutics to a “hold” rating in a research note on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Relmada Therapeutics in a report on Wednesday, January 28th. Finally, Mizuho set a $10.00 target price on shares of Relmada Therapeutics in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Relmada Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC acquired a new stake in shares of Relmada Therapeutics during the 4th quarter worth about $35,041,000. Squadron Capital Management LLC bought a new position in Relmada Therapeutics during the 4th quarter valued at about $32,361,000. Adage Capital Partners GP L.L.C. acquired a new position in Relmada Therapeutics in the fourth quarter valued at about $20,624,000. Marshall Wace LLP grew its stake in Relmada Therapeutics by 1,072.4% during the fourth quarter. Marshall Wace LLP now owns 3,189,662 shares of the company’s stock worth $15,406,000 after buying an additional 2,917,609 shares during the last quarter. Finally, Orbimed Advisors LLC bought a new stake in Relmada Therapeutics during the fourth quarter worth about $12,609,000. 45.24% of the stock is owned by institutional investors.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.